Short-term effects of leptin on lipid metabolism in the rat  by López-Soriano, Joaquı́n et al.
Short-term e¡ects of leptin on lipid metabolism in the rat
Joaqu|Łn LoŁpez-Soriano, Neus CarboŁ, Francisco J. LoŁpez-Soriano, Josep M. ArgileŁs*
Departament de Bioqu|Łmica i Biologia Molecular, Facultat de Biologia, Universitat de Barcelona, Diagonal 645, 08071-Barcelona, Spain
Received 19 June 1998
Abstract In this study, we have examined the short-term effects
of leptin on lipid metabolism in the rat. Acute leptin adminis-
tration induced hypertriglyceridaemia (31% increase in plasma
triacylglycerols) which was not associated with changes in
lipoprotein lipase activity in white adipose tissue. Surprisingly,
leptin administration did not induce any changes in the lipogenic
rate in either white adipose tissue or liver. Leptin administration
caused a decreased tissue uptake of exogenous 14C-triacylglyc-
erols. These data suggest that leptin induces important changes
in lipid uptake in adipose tissue and skeletal muscle which could
be responsible for the observed hypertriglyceridaemia.
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1. Introduction
The ob gene protein, also known as leptin, is a 16-kDa
protein synthesized and secreted by adipose tissue in propor-
tion to fat stores. It has been proposed to have a role as a
ponderostat signal informing the brain of the adipose tissue
mass and therefore to be involved in the regulation of energy
balance [1^4]. Administration of recombinant leptin reduces
food intake and produces weight loss [2,3,5], increases energy
expenditure [2,6] and increases plasma insulin and glucose [7]
in ob/ob mice. Leptin also decreases food intake and body
weight in non-obese mice [2,3], therefore a failure to produce
adequate amounts of leptin or resistance to its central actions
would result in the development of obesity.
Leptin is thought to exert its actions on energy homeostasis
through the long form of the leptin receptor which is present
in the hypothalamus (although at least ¢ve other receptor
forms have been cloned) and in certain peripheral organs,
including adipose tissue. In the hypothalamus, leptin may
modulate the activity of neuropeptide Y (NPY), glucagon-
like peptide-1 (GLP-1), and other peptides that in£uence feed-
ing behaviour [8^11]. Indeed, Fan et al. [12] and Huszar et al.
[13] have shown that the melanocortin-4 receptor and its pep-
tide ligand, melanocyte-stimulating hormone (MSH), are im-
portant in the pathogenesis of obesity in mice with the yellow
Agouti mutation. Very recently, Kristensen et al. [14] have
shown that CART (cocaine- and amphetamine-regulated tran-
script) is a satiety factor that may mediate hypothalamic lep-
tin action. Many studies have indicated that leptin and obesity
are clearly associated. Thus, ob/ob mice are obese and mani-
fest great similarities to animals with lesions in the ventrome-
dial hypothalamus, leading to the prediction that leptin acts
on the central nervous system to suppress appetite. This hy-
pothesis is supported by the fact that intraventricular infusion
of leptin is more e¡ective than intraperitoneal administration
in causing weight loss in mice [5]. However, pair-feeding stud-
ies in both obese and lean mice have demonstrated that leptin
e¡ects cannot be accounted for entirely by reduced food in-
take [15]. Thus it is not clear whether leptin acts solely
through its central e¡ects or peripherally via functional recep-
tors detected in non-neuronal tissues, such as lung, liver, kid-
ney, gonads and fat [16^19]. In addition other molecules may
also be involved. Thus, tumour necrosis factor-K (TNF) con-
tributes to obesity-related hyperleptinemia by regulating leptin
release from adipocytes [20]. Indeed, the elevated expression
of the cytokine in adipose tissue during obesity [21] may be
responsible for the increased leptin production [20]. Leptin
also increases the expression of uncoupling proteins [22],
UCP1 (present only in brown adipose tissue) and UCP2
(widely distributed), and this may certainly be related to the
e¡ects of the ob protein on energy expenditure. In fact, the
e¡ects on UCP1 could be mediated by L3-adrenergic receptors
[22].
In spite of the plethora of investigations that have appeared
since its recent discovery, very few studies have concentrated
on leptin metabolic e¡ects, particularly in relation to lipid
metabolism. Therefore it was the aim of the present investi-
gation to see if the acute administration of leptin to rats could
have any e¡ects on lipid metabolism.
2. Materials and methods
2.1. Animals
All animals (male Wistar rats weighing 65^85 g) were fed ad libitum
on a chow diet consisting (by weight) of 54% carbohydrate, 17%
protein and 5% fat (the residue was non-digestible material), with
free access to drinking water, and were maintained at an ambient
temperature of 22 þ 2‡C with a 12-h light/12-h dark cycle (lights on
from 08.00 h).
Animals were intravenously injected with murine recombinant lep-
tin (1 mg/kg body weight) dissolved in sterile saline, and sacri¢ced 3.5
h later under diethyl ether anaesthesia. Samples of arterial blood and
tissues (skeletal muscle, heart, adipose tissue and liver) were rapidly
collected for further processing.
2.2. Biochemicals
Biochemicals were all reagent grade and obtained either from Boeh-
ringer Mannheim S.A. (Barcelona, Spain) or from Sigma Chemical
Co. (St. Louis, MO, USA). Radiochemicals were purchased from
Amersham Int. (Amersham, Bucks., UK). Recombinant murine leptin
was purchased from PeproTech Ltd. (London, UK). The purity of the
reagent was greater than 95% and it contained less than 0.1 ng/Wg of
endotoxin.
2.3. Circulating leptin and insulin
Plasma leptin was determined by means of a rat radioimmunoassay
kit (Linco Res. Inc., St. Charles, MO, USA). Plasma insulin was
quanti¢ed with a rat radioimmunoassay kit from Amersham Int.
(Amersham, Bucks., UK).
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2.4. Circulating triacylglycerols and cholesterol
Plasma triacylglycerols were measured by the method of Eggstein
and Kreutz [23]. Plasma cholesterol was measured by means of a kit
(Menarini Diagnostics, Italy).
2.5. Lipoprotein lipase activity
Tissue lipoprotein lipase (LPL) activity was measured by a modi¢-
cation of the technique of Nilsson-Ehle and Ekman [24]. Tissue sam-
ples (retroperitoneal adipose tissue and tibialis muscle) were homog-
enized and used in an assay system containing [3H]triolein as
substrate; [3H]-fatty acids released after a 30-min incubation period
were extracted and determined by the method of Nilsson-Ehle and
Schotz [25].
2.6. Lipogenic rate in vivo
Tissue lipogenesis and liver cholesterogenesis were measured by
using 3H2O as previously described [26]. At 1 h before being sacri-
¢ced, the animals were injected with 0.2 ml (2 mCi) of 3H2O intra-
peritoneally. Tissues were saponi¢ed and fatty acids extracted by the
method of Stansbie et al. [27].
2.7. Lipid oxidation and tissue lipid accumulation
The metabolic fate of an orally administered [14C]-lipid load was
examined as described by Oller do Nascimiento and Williamson [28]
in another group of animals of the same characteristics indicated
above. About 0.5 g (2 WCi) of [14C]triolein per rat were given enterally
by gastric intubation, without anaesthetic but with minimal stress to
the animal. After 3.5 h, the animals were killed, using diethyl ether as
anaesthesia. The gastrointestinal tract (plus contents) was homoge-
nized in 150 ml of 3% (w/v) HClO4. Samples were taken of liver,
interscapular brown adipose tissue (IBAT), retroperitoneal white adi-
pose tissue (WAT), hindleg muscle and heart. Samples of tissues were
saponi¢ed and the lipid was extracted [27]. The extracted fatty acids
were dissolved in 8 ml of liquid scintillation £uid for determination of
[14C]-lipid formation. Triolein absorption was calculated by subtract-
ing total gastrointestinal radioactivity from that administered.
2.8. Statistical analysis
Statistical analysis of the data was performed by means of Student’s
t-test.
3. Results and discussion
In spite of the plethora of investigations devoted to leptin,
very few have considered the e¡ects of leptin on intermediate
metabolism. The results presented here constitute the ¢rst
study of the short-term e¡ects of leptin administration on
lipid metabolism in the rat. Previous investigations have
shown that in addition to being produced by adipocytes [1]
and having a role in the control of food intake [29], leptin has
important e¡ects on thermogenesis and metabolism. Leptin
stimulates glucose metabolism increasing glucose turnover
and decreasing liver glycogen [30]. Leptin also seems to act
on muscle metabolism where it increases glycogen [30] and
induces fatty acid oxidation [31]. This last e¡ect is observed
in incubating muscle, therefore demonstrating that leptin ef-
fects are direct. In spite of these studies, very few have con-
centrated on the metabolism of the adipocyte, the leptin-pro-
ducing cell. Very recent studies suggest that leptin can directly
modulate adipose tissue lipolysis, both in normal rats [32] and
obese (ob/ob) mice [33], but not in obese fa/fa rats or db/db
mice, where there is a lack of leptin receptor function. Leptin
produced by the fat cells could constitute a mechanism to
modulate its own lipid metabolism. The main objective of
this investigation was therefore to analyze the short-term ef-
fects of exogenous leptin administration on lipid metabolism,
particularly in adipose tissue.
Following leptin administration, the levels of the protein
increased 7.8-fold in relation with the non-treated controls
(Table 1). Interestingly, leptin administration did not cause
any changes in circulating insulin (Table 1). It has been pre-
viously reported that leptin impairs metabolic actions of in-
sulin in adipose tissue [34] and muscle [31]. In addition, the
circulating levels of leptin seem to be correlated with those of
circulating insulin [35]. However, non-insulin-dependent dia-
betics show leptin levels which do not di¡er from those of
non-diabetic humans of the same body mass index [36].
Although ob gene expression in rats is up-regulated by insulin
under euglycaemic conditions, interestingly short-term insulin
administration does not increase leptin secretion in humans
[37]. Our data seem to indicate that the contrary is also true,
at least in experimental animals.
Leptin administration resulted in an increase in plasma tri-
acylglycerols (31%) which was not associated with changes in
total plasma cholesterol (Table 2). We therefore decided to
investigate the mechanism responsible for the leptin-induced
hypertriglyceridaemia. One of the factors that could be in-
volved is a decreased clearance of circulating triacylglycerols
in the form of either chylomicra or very low density lipopro-
teins (VLDL). In fact, the uptake of this type of triacylglycer-
ols is mediated through the activity of lipoprotein lipase
(LPL), an enzyme present in the endothelium of many tissues
that cleaves triacylglycerols into fatty acids and glycerol and
allows the cell internalization of these metabolites. Surpris-
ingly, leptin administration did not have any e¡ects on LPL
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Table 1
Plasma leptin and insulin levels following leptin administration
Experimental group
Control Leptin-treated
Leptin (ng/ml) 0.74 þ 0.13 5.78 þ 1.63***
Insulin (ng/ml) 0.60 þ 0.03 0.63 þ 0.07
For more details, see Section 2. The values are mean þ S.E.M. for ¢ve
animals. Statistical signi¢cance of the results (Student’s t-test) (leptin
vs. control): ***P6 0.001.
Table 2
Tissue lipoprotein lipase activity and circulating triacylglycerols and cholesterol in leptin-treated rats
Tissue Experimental group
Control Leptin-treated
Plasma triacylglycerols (mg/100 ml) 72.2 þ 1.7 94.8 þ 7.4*
Plasma cholesterol (mg/100 ml) 83.5 þ 2.6 80.6 þ 4.1
LPL activity
White adipose tissue (retroperitoneal fat pads) 0.830 þ 0.067 0.687 þ 0.069
Skeletal muscle (tibialis) 0.158 þ 0.006 0.141 þ 0.006
For further details, see Section 2. Lipoprotein lipase (LPL) activity is expressed as nmol of fatty acid released/min per mg of tissue. The results are
mean values þ S.E.M. for ¢ve animals. Statistical signi¢cance of the di¡erences (leptin vs. control) (Student’s t-test) : *P6 0.05.
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activity in white adipose tissue. It has been previously re-
ported that chronic leptin administration (20 mg/kg/day) in
mice resulted in decreased circulating triacylglycerols with
an increase in LPL gene expression [22]. Similarly Chen et
al. [38] reported that sustained hyperleptinemia of 8 ng/ml
induced for 28 days by infusing a recombinant adenovirus
containing the rat leptin cDNA (AdCMV-leptin) in rats re-
sulted in hypotriglyceridaemia. It has to be pointed out, how-
ever, than these chronic leptin administration models involve
an important reduction in food intake which partly accounts
for the reduced triacylglycerol concentration. To further in-
vestigate the cause of the hypertriglyceridaemia, we decided to
analyze the lipogenic rate in vivo as estimated by the incor-
poration of 3H2O into tissue lipids. Interestingly, the lipogenic
rate was unchanged in the liver, suggesting that an increased
hepatic fatty acid synthesis and ulterior esteri¢cation and
VLDL release were not involved in the increase in circulating
triacylglycerols that followed leptin administration (Table 3).
Both WAT and IBAT lipogenic rates were also unaltered by
leptin administration.
From the results obtained it seems quite clear that an en-
hanced liver lipogenic rate could not account for the leptin-
induced hypertriglyceridaemia. In spite of the fact that admin-
istration of the ob protein resulted in no signi¢cant changes in
tissue LPL activity, a tendency for the activity values to be
lower is observed in both adipose tissue and skeletal muscle.
Since adipose tissue and skeletal muscle represent about 50%
of body weight in the rat [39], a small decrease in LPL activity
could be responsible for the observed increase in circulating
triacylglycerols. To further investigate this possibility, we de-
cided to examine the tissue uptake of an exogenous triacylgly-
cerol load (Table 4). The results clearly show that the total
uptake of [14C]triolein was decreased both in skeletal (34%)
and cardiac (30%) muscles and white (34%) and brown (57%)
adipose tissues, while no changes in uptake were observed in
liver (Table 4). Interestingly, leptin administration resulted in
no changes in the intestinal absorption of the exogenous lipid
load (Table 4). The results presented here are in agreement
with those of Chen et al. [38] demonstrating that in vivo
hyperleptinemia (induced in normal rats by adenovirus gene
transfer) completely ablated fat tissue suggesting a speci¢c
lipoatrophic activity for leptin. The same research group
[40] has shown that leptin depletes triacylglycerol content in
the liver, skeletal muscle and pancreas without increasing fatty
acid oxidation, thus suggesting intracellular oxidation. Our
results are also in full agreement with those of Muoio et al.
[31], clearly demonstrating that leptin alters lipid partitioning
in skeletal muscle and suggesting that, in some cases, the
skeletal muscle mass can exert important e¡ects on triglycer-
idaemia.
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Table 3
Tissue lipogenic and cholesterogenic rates in leptin-treated rats
Tissue Experimental group
Control Leptin-treated
Liver a 9.61 þ 1.22 9.49 þ 1.83
b 41.1 þ 5.41 41.7 þ 8.92
c 1.73 þ 0.14 1.88 þ 0.26
d 7.42 þ 0.48 8.26 þ 1.26
White adipose tissue a 5.38 þ 1.10 7.36 þ 1.75
b 0.85 þ 0.20 0.88 þ 0.19
Brown adipose tissue a 29.0 þ 5.26 23.6 þ 4.00
b 7.33 þ 0.54 8.47 þ 0.78
For further details, see Section 2. Tissue lipogenesis is expressed both as: (a) Wmol of 3H2O/h/g of tissue and (b) Wmol of 3H2O/h/total tissue (in the
case of adipose tissue, only retroperitoneal fat pads were considered). Cholesterogenic rate was calculated as (c) Wmol of 3H2O/h (non-saponi¢ed
lipids)/g of tissue or (d) Wmol of 3H2O/h (non-saponi¢ed lipids)/total tissue. The results are mean values þ S.E.M. for ¢ve animals.
Table 4
Intestinal absorption and metabolic fate of [14C]triolein in leptin-treated rats
Parameter Experimental group
Control Leptin-treated
[14C]Triolein absorption (% of administered dose) 85.4 þ 2.7 86.4 þ 1.6
[14C]-Lipid accumulation (% of absorbed dose)
Liver 0.975 þ 0.063 0.956 þ 0.059
White adipose tissue 2.660 þ 0.330 1.260 þ 0.380*
Brown adipose tissue 1.422 þ 0.298 0.610 þ 0.177*
Skeletal muscle (tibialis) 0.228 þ 0.022 0.151 þ 0.024*
Heart 0.246 þ 0.013 0.173 þ 0.010**
For further details, see Section 2. Intestinal absorption was assessed 3.5 h after an oral [14C]triolein administration. Tissue lipid accumulation values
are expressed as % of absorbed dose/g. The results are mean values þ S.E.M. for ¢ve animals. Values that are signi¢cantly di¡erent (leptin vs.
control) by Student’s t-test are indicated by: *P6 0.05, **P6 0.01.
J. LoŁpez-Soriano et al./FEBS Letters 431 (1998) 371^374 373
References
[1] Zhang, Y., Proenca, R., Ma¡ei, M., Barone, M., Leopold, L. and
Friedman, J.M. (1994) Nature 372, 425^432.
[2] Pelleymounter, M.A., Callen, M.J., Baker, M.B., Hecht, R., Win-
ters, D., Boone, T. and Collins, F. (1995) Science 269, 540^543.
[3] Halaas, J.L., Gajiwala, K.S., Ma¡ei, M., Cohen, S.L., Chait,
B.T., Rabinowitz, D., Lallone, R.L., Burley, S.K. and Friedman,
J.M. (1995) Science 269, 543^546.
[4] Caro, J.F., Sinha, M.K., Kolaczynski, J.W., Zhang, P.L. and
Considine, R.V. (1996) Diabetes 45, 1455^1462.
[5] Camp¢eld, L.A., Smith, F.J., Guisez, Y., Devos, R. and Burn, P.
(1995) Science 269, 546^549.
[6] Levin, N., Nelson, C., Gurney, A., Vandlen, R. and De Sauvage,
F. (1996) Proc. Natl. Acad. Sci. USA 93, 1726^1730.
[7] Schwartz, M.W., Baskin, D.G., Bukowski, T.R., Kuijper, J.L.,
Foster, D., Lasser, G., Prunkard, D.E., Porte, D., Woods, S.C.,
Seeley, R.J. and Weigle, D.S. (1996) Diabetes 45, 531^535.
[8] Schwartz, M.W., Seeley, R.J., Camp¢eld, L.A., Burn, P. and
Baskin, D.G. (1996) J. Clin. Invest. 98, 1101^1106.
[9] Goldstone, A.P., Mercer, J.G., Gunn, I., Moar, K.M., Edwards,
C.M., Rossi, M., Howard, J.K., Rasheed, S., Turton, M.D.,
Small, C., Heath, M.M., O’Shea, D., Steere, J., Meeran, K.,
Ghatei, M.A., Hoggard, N. and Bloom, S.R. (1997) FEBS
Lett. 415, 134^138.
[10] Wang, Q., Bing, C., Al-Barazanji, K., Mossakowaska, D.E.,
Wang, X.M., McBay, D.L., Neville, W.A., Taddayon, M., Pick-
avance, L., Dryden, S., Thomas, M.E., McHale, M.T., Gloyer,
I.S., Wilson, S., Buckingham, R., Arch, J.R., Trayhurn, P. and
Williams, G. (1997) Diabetes 46, 335^341.
[11] Sahu, A. (1998) Endocrinology 139, 795^798.
[12] Fan, W., Boston, B.A., Kesterson, R.A., Hruby, V.J. and Cone,
R.D. (1997) Nature 385, 165^168.
[13] Huszar, D., Lynch, C.A., Fairchild-Huntress, V., Dunmore, J.H.,
Fang, Q., Berkemeier, L.R., Gu, W., Kesterson, R.A., Boston,
B.A., Cone, R.D., Smith, F.J., Camp¢eld, L.A. and Lee, F.
(1997) Cell 88, 131^141.
[14] Kristensen, P., Judge, M.E., Thim, L., Ribel, U., Christjansen,
K.N., Wul¡, B.S., Clausen, J.T., Jensen, P.B., Madsen, O.D.,
Vrang, N., Larsen, P.J. and Hastrup, S. (1998) Nature 393, 72^
76.
[15] Levin, N., Nelson, C., Gurney, A., Vandlen, R. and De Sauvage,
F. (1996) Proc. Natl. Acad. Sci. USA 93, 1726^1730.
[16] Hamann, A. and Matthaei, S. (1996) Exp. Clin. Endocrinol. Dia-
betes 104, 293^300.
[17] Levin, B.E. and Routh, V.H. (1996) Am. J. Physiol. 271, R491^
R500.
[18] Schwartz, M.W., Seeley, R.J., Camp¢eld, L.A., Burn, P. and
Baskin, D.G. (1996) J. Clin. Invest. 98, 1101^1106.
[19] Trayhurn, P. and Rayner, D.V. (1996) Biochem. Soc. Trans. 24,
565^570.
[20] Kirchgessner, T.G., Uysal, K.T., Wiesbrock, S.M., Marino,
M.W. and Hotamisligil, G.S. (1997) J. Clin. Invest. 100, 2777^
2782.
[21] Hotamisligil, G.S., Shargill, N.S. and Spiegelman, B.M. (1993)
Science 259, 87^90.
[22] Sarmiento, U., Benson, B., Kaufman, S., Ross, L., Qi, M.,
Scully, S. and DiPalma, C. (1997) Lab. Invest. 77, 243^256.
[23] Eggstein, M. and Kreutz, F.H. (1966) Klin. Wochenschr. 44,
262^267.
[24] Nilsson-Ehle, P. and Ekman, R. (1977) Artery 3, 197^209.
[25] Nilsson-Ehle, P. and Schots, M.C. (1976) J. Lipid Res. 17, 536^
541.
[26] Robinson, A.M., Girard, J.R. and Williamson, D.H. (1978) Bio-
chem. J. 176, 343^346.
[27] Stansbie, D., Brownsey, R.W., Crettaz, M. and Denton, R.M.
(1986) Biochem. J. 160, 413^416.
[28] Oller do Nascimiento, C.M. and Williamson, D.H. (1986) Bio-
chem. J. 239, 233^236.
[29] Friedman, J.M. (1997) Nature 385, 119^120.
[30] Kamohara, S., Burcelin, R., Halaas, J.L., Friedman, J.M. and
Charron, M.J. (1997) Nature 389, 374^377.
[31] Muoio, D.M., Dohn, G.L., Fiedorek, F.T., Tapscott, E.B. and
Coleman, R.A. (1997) Diabetes 46, 1360^1363.
[32] Siegrist-Kaiser, C.A., Pauli, V., Juge-Aubry, C.E., Boss, O., Per-
nin, A., Chin, W.W., Cusin, I., Rohner-Jeanrenaud, F., Burger,
A.G., Zapf, J. and Meier, C.A. (1997) J. Clin. Invest. 100, 2858^
2864.
[33] Fruºhbeck, G., Aguado, M. and Mart|Łnez, J.A. (1997) Biochem.
Biophys. Res. Commun. 240, 590^594.
[34] Muller, G., Ertl, J., Gerl, M. and Preibisch, G. (1997) J. Biol.
Chem. 272, 10585^10593.
[35] Zimmet, P.Z. and Collier, G.R. (1996) Med. J. Aust. 164, 393^
394.
[36] Ha¡ner, S.M., Stern, M.P., Miettinen, H., Wei, M. and Ginger-
ich, R.L. (1996) Diabetes 45, 822^824.
[37] Kolaczynski, J.W., Nyce, M.R., Considine, B.V., Boden, G.,
Nolan, J.J., Henry, R., Mudaliar, S.R., Olefsky, J. and Caro,
J.F. (1996) Diabetes 45, 699^701.
[38] Chen, G., Koyama, K., Yuann, X., Lee, Y., Zhou, Y.T., O’Doh-
erty, R., Newgard, C.B. and Unger, R.H. (1996) Proc. Natl.
Acad. Sci. USA 93, 14795^14799.
[39] Arola, L., Herrera, E. and Alemany, M. (1979) Rev. Esp. Fisiol.
35, 215^218.
[40] Shimabukuro, M., Koyama, K., Cheng, G., Wang, M.Y., Trieu,
F., Lee, Y., Newgard, C.B. and Unger, R.H. (1997) Proc. Natl.
Acad. Sci. USA 94, 4637^4641.
FEBS 20547 24-7-98
J. LoŁpez-Soriano et al./FEBS Letters 431 (1998) 371^374374
